{"url_path":"/sec/algs/8-k/2026-06-26/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1799448/0001193125-26-285426-index.html","accession_number":"0001193125-26-285426","cik":"0001799448","ticker":"ALGS","issuer_name":"Aligos Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1799448/0001193125-26-285426-index.html","primary_entity_key":"0001799448","primary_entity_name":"Aligos Therapeutics, Inc."},"word_count":442,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\nAt the Annual Meeting, the Company’s stockholders voted on five proposals, each of which is described in more detail in the Proxy Statement. Only stockholders of record as of the close of business on April 27, 2026, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 5,388,223 shares of the Company’s voting common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:\n\nProposal 1. The election of two Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are duly elected and qualified. The results of the vote were as follows:\n\n \n\nNominee\n\n  \nVotes For\n \n  \nVotes Withheld\n \n  \nBroker Non-Votes\n\nBridget Martell, M.A., M.D.\n\n  \n \n2,092,164\n \n  \n \n88,707\n \n  \n1,613,003\n\nCarole Nuechterlein, J.D.\n\n  \n \n2,086,481\n \n  \n \n94,390\n \n  \n1,613,003\n\nProposal 2. The ratification of the selection by the audit committee of the Board of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. The results of the vote were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n3,786,255\n \n7,484\n \n135\n\nAs a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.\n\nProposal 3. The approval of an amendment to the ESPP to (i) reserve an additional 500,000 shares for issuance under the Amended ESPP and make them available for purchase under the Amended ESPP’s offering periods, and (ii) eliminate the “evergreen” provision in the ESPP. The results of the vote were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker\n\nNon-Votes\n\n2,161,966\n \n17,797\n \n1,108\n \n1,613,003\n\n \n\nProposal 4. The approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers. The results of the vote were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker\n\nNon-Votes\n\n2,074,434\n \n98,358\n \n8,079\n \n1,613,003\n\nProposal 5. The approval, on a non-binding, advisory basis, of the frequency of future advisory votes on the compensation of the Company’s named executive officers. The results of the vote were as follows:\n\n \n\nOne Year\n\n \n\nTwo Years\n\n \n\nThree Years\n\n \n\nAbstentions\n\n \n\nBroker\n\nNon-Votes\n\n2,077,884\n \n2,947\n \n97,350\n \n2,690\n \n1,613,003\n\nBased on these voting results, and the recommendation of the Company’s Board that was included in the Proxy Statement, the Company has determined that it will hold future advisory votes on the compensation of the Company’s named executive officers on an annual basis until the next stockholder advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers."}